Latest Breaking News On - Fierce pharma - Page 1 : vimarsana.com

ASCO: With first-in-class win, Sanofi s Sarclisa looks to step out of J&J s multiple myeloma shadow

ASCO: With first-in-class win, Sanofi s Sarclisa looks to step out of J&J s multiple myeloma shadow
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Bristol myers squibb revlimidTakeda velcadeJj darzalex fasproPeter adamsonJohnson darzalexAmgen kyprolisBristol myers squibbFierce pharma

BlueSphere Bio to Present Corporate Update and Participate in a Panel Discussion at the 2024 BIO International Convention

BlueSphere Bio to Present Corporate Update and Participate in a Panel Discussion at the 2024 BIO International Convention
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San diego convention centerUnited statesSan diegoAngus liuKim jaffeBluesphere bioAndrew mielachKeir loiaconoLifesci communicationsPanel discussionHead of business development strategyWhile the companyInternational conventionCompany contactSphere bioPresent corporate update

Novartis ASCO booth uses AR to simulate patient burden

Novartis ASCO booth uses AR to simulate patient burden
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

United statesGail horwoodLas vegasAmerican society of clinical oncologyBig pharmaAmerican societyClinical oncologyFierce pharmaVision proThan just

ASCO: Bristol Myers unveils I-O triplet data in melanoma as Iovance touts paradigm-changing combo result

Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches.

United statesGraf finckensteinFriedrich graf finckensteinBristol opdivoMerck coAmerican society of clinical oncologyBristol myers squibbBristol myerAmerican societyClinical oncologyLeerink partnersFierce pharma

ASCO: Merck KGaA s Bavencio combo misses survival mark in RCC

Although the overall survival miss won't cost Bavencio its FDA approval, it puts the drug further behind rival PD-1 combos from Merck & Co. and BMS.

New yorkUnited statesMerck keytrudaKeytruda lenvimaPeter guenterExelixi cabometyxMerck kgaa bavencioInternational metastaticMerck kgaaBristol myers squibbMerck kgaAmerican society of clinical oncologyDatabase consortiumMerck coAmerican societyClinical oncology